Healthcare Today Bahrain: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Today Bahrain.

Press releases published on July 9, 2026

11 hours ago

Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026

Indeterminate GlobeNewswire

11 hours ago

Sam’s Club® and Weight Watchers® Collaborate to Expand Access to Affordable, Holistic Wellness Experiences for Members

Indeterminate GlobeNewswire

11 hours ago

VisCardia Implants First U.S. Patient in RECOVER-HF Pivotal Trial

Indeterminate GlobeNewswire

11 hours ago

New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management

Indeterminate GlobeNewswire

11 hours ago

UREVO Wins Red Dot Award 2026 for AI-Powered Wireless Recovery Boots, Recognized for Real-Time, AI-Adaptive Recovery

Indeterminate GlobeNewswire

11 hours ago

Atsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease

Indeterminate GlobeNewswire

11 hours ago

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

Indeterminate GlobeNewswire

11 hours ago

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

Indeterminate GlobeNewswire

11 hours ago

Tris Pharma Launches Adneuris Therapeutics to Advance a New Era in Pain Medicine

Indeterminate GlobeNewswire

12 hours ago

Fangzhou Named to KPMG China Healthcare 50 for AI-Powered Chronic Disease Care

Indeterminate GlobeNewswire

12 hours ago

What Clinicians Ask About Cartilage Regeneration Supplements: Answering the Clinical Questions Around Cartigenix HP®

Indeterminate GlobeNewswire

12 hours ago

INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC

Indeterminate GlobeNewswire

12 hours ago

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

Indeterminate GlobeNewswire

12 hours ago

NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner

Indeterminate GlobeNewswire

13 hours ago

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

Indeterminate GlobeNewswire

16 hours ago

Cytosurge’s CellEDIT Conquers "Impossible" Genome Engineering Challenges

Indeterminate GlobeNewswire

18 hours ago

Dysport® est la première toxine botulinique à obtenir des résultats préliminaires positifs de phase III, à la fois dans la migraine épisodique et dans la migraine chronique.

Indeterminate GlobeNewswire

18 hours ago

Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.

Indeterminate GlobeNewswire